Evidence map›Paper›PMID 36324579›Full record

ArticleFrontiers in oncology2022

A novel vector for magnetic resonance imaging-guided chemo-photothermal therapy for cancer.

Ji Chuan Kong, Yang Li, Wang Ma, Yu Rong Du, Lei Liu, Tian Tian Qu, Shuo Shuo Liu, Meng Li Wang, Wei Dou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ji Chuan KongMedical College, Henan Polytechnic University, Jiaozuo, China.
Yang LiMedical College, Henan Polytechnic University, Jiaozuo, China.
Wang MaMedical College, Henan Polytechnic University, Jiaozuo, China.
Yu Rong DuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Lei LiuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Tian Tian QuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Shuo Shuo LiuMedical College, Henan Polytechnic University, Jiaozuo, China.
Meng Li WangMedical College, Henan Polytechnic University, Jiaozuo, China.
Wei DouMedical College, Henan Polytechnic University, Jiaozuo, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As an effective strategy for oncotherapy, developing efficacious drug delivery systems for cancer combination therapy remains a major challenge. To improve nanodrug biocompatibility and composite function facilitating their clinical conversion application, a novel nanocarrier was presented by a facile method through conjugating humic acid with gadolinium ions to synthesize HA-Gd with good biocompatibility and dispersity. HA-Gd exhibited high photothermal conversion efficiency up to 38%, excellent photothermal stability, and high doxorubicin (DOX) loading capacity (93%) with pH-responsive release properties. HA-Gd loading DOX showed a combined chemo-photothermal inhibitory effect on tumor cells. Compared with lipid-DOX, HA-Gd-DOX had a more significant inhibitory effect on tumor growth and fewer side effects. T

Indexed as

combination therapyHA-Gdhumic acidsmagnetic resonance imagingnanocarrier

Identifiers

PMID36324579
PMCPMC9618661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.